4.6 Review

Coronavirus Disease 2019-Associated Thrombosis and Coaculopathy: Review of the Pathophysiological Characteristics and Implications for Antithrombotic Management

Journal

Publisher

WILEY
DOI: 10.1161/JAHA.120.019650

Keywords

anticoagulant therapy; antiplatelet therapy; coronavirus disease 2019; endothelium; platelets; severe acute respiratory syndrome coronavirus-2; thrombosis

Ask authors/readers for more resources

COVID-19 caused by severe acute respiratory syndrome coronavirus-2 can lead to intense inflammatory and prothrombotic states, with cardiovascular implications and an increased risk of thrombotic events. The virus utilizes angiotensin-converting enzyme 2 as a functional receptor, which is highly expressed in the respiratory and cardiovascular systems.
Coronavirus disease 2019 (COVID-19) is an infectious disease caused by severe acute respiratory syndrome coronavirus-2, which has posed a significant threat to global health. Although the infection is frequently asymptomatic or associated with mild symptoms, in a small proportion of patients it can produce an intense inflammatory and prothrombotic state that can lead to acute respiratory distress syndrome, multiple organ failure, and death. Angiotensin-converting enzyme 2, highly expressed in the respiratory system, has been identified as a functional receptor for severe acute respiratory syndrome coronavirus-2. Notably, angiotensin-converting enzyme 2 is also expressed in the cardiovascular system, and there are multiple cardiovascular implications of COVID-19. Cardiovascular risk factors and cardiovascular disease have been associated with severe manifestations and poor prognosis in patients with COVID-19. More important, patients with COVID-19 may have thrombotic and coagulation abnormalities, promoting a hypercoagulable state and resulting in an increased rate of thrombotic and thromboembolic events. This review will describe the pathophysiological characteristics of the cardiovascular involvement following infection by severe acute respiratory syndrome coronavirus-2, with a focus on thrombotic and thromboembolic manifestations and implications for antithrombotic management.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available